Market Place
Sourcing Support
EU Approves LeukoStrat CDx FLT3 Assay For Vanglyta Therapy
08 Oct 2024 //
BUSINESSWIRE
Daiichi Sankyo`s Vanflyta (quizartinib) Receives Approval in Europe
21 Nov 2023 //
EMA
VANFLYTA® Approved in the EU as the First FLT3 Inhibitor
09 Nov 2023 //
BUSINESSWIRE
Quizartinib Recommended for Approval in EU by CHMP for Patients with AML
15 Sep 2023 //
BUSINESSWIRE
Quizartinib Plus Induction Chemotherapy Provides Survival Benefit in AML
08 Sep 2023 //
ONCLIVE
Frontline Quizartinib Plus Chemotherapy Shows Curative Potential in FLT3-ITD
17 Aug 2023 //
ONCLIVE
VANFLYTA® (quizartinib) Now Available from Onco360
09 Aug 2023 //
BUSINESSWIRE
Japan`s Daiichi Sankyo gets US FDA nod for blood cancer treatment
21 Jul 2023 //
PRESS RELEASE
FDA pushes back PDUFA date for Daiichi`s AML drug quizartinib over REMS updates
22 Apr 2023 //
ENDPTS
Quizartinib NDA Review for Patients with Newly Diagnosed FLT3-ITD Positive AML
20 Apr 2023 //
BUSINESSWIRE
Quizartinib Granted Priority Review in the U.S. for Patients
24 Oct 2022 //
BUSINESSWIRE
Quizartinib Supplemental New Drug Application Submitted in Japan
30 Aug 2022 //
PRESS RELEASE
Quizartinib MAA Validated by EMA for FLT3-ITD Positive AML
23 Aug 2022 //
BUSINESSWIRE
Daiichi Sankyo tees up fresh approval request with AML data
14 Jun 2022 //
FIERCEBIOTECH
Quizartinib Plus Chemotherapy Significantly Improved OS Compared to Chemotherapy
11 Jun 2022 //
BUSINESSWIRE
Daiichi could be rewarded for persisting with Vanflyta
19 Nov 2021 //
EVALUATE
Daiichi Announces Positive Topline Results from Phase 3 QuANTUM-First Trial
19 Nov 2021 //
TRIALSITENEWS
Quizartinib Added to Chemotherapy Demonstrates Superior Overall Survival in AML
18 Nov 2021 //
BUSINESSWIRE
EMA committee rejects Daiichi Sankyo`s MAA for quizartinib
21 Oct 2019 //
PHARMABIZ
Daiichi starts challenging Astellas for Japanese AML market
11 Oct 2019 //
PMLIVE
Astellas` AML drug wins over CHMP — strengthening lead on Daiichi Sankyo
20 Sep 2019 //
ENDPTS
FDA nixes Daiichi’s quizartinib after Japanese regulators wave it through
22 Jun 2019 //
FIERCE BIOTECH
Daiichi Sankyo`s VANFLYTA® Receives Approval in Japan
19 Jun 2019 //
PR NEWSWIRE
Takeda outlook, generics suit and more—FiercePharmaAsia
17 May 2019 //
FIERCE PHARMA
Daiichi Sankyo ‘disappointed’ as FDA experts spurn AML drug voterare tumor drug
15 May 2019 //
ENDPTS
FDA questions credibility of Daiichi data ahead of AdComm
14 May 2019 //
FIERCE BIOTECH
Daiichi`s Xospata rival pushed back by FDA
05 Apr 2019 //
FIERCE BIOTECH
Daiichi Sankyo Initiates Combination Study of 2 Investgl Agents AML
20 Dec 2018 //
PR NEWSWIRE
Daiichi Sankyo submits NDA in Japan for leukemia drug
19 Oct 2018 //
BIOSPECTRUM ASIA
Daiichi Sankyo seeks Japanese health ministry nod for quizartinib
17 Oct 2018 //
PHARMABIZ
Daiichi Sankyo`s quizartinib receives US FDA breakthrough therapy status
02 Aug 2018 //
PHARMABIZ
As NDA talks loom, FDA hands Daiichi Sankyo breakthrough on quizartinib
02 Aug 2018 //
ENDPTS
Daiichi Sankyo presents positive results from QuANTUM-R ph3 study quizartinib
18 Jun 2018 //
PHARMABIZ
